Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease
Status:
Completed
Trial end date:
2019-02-06
Target enrollment:
Participant gender:
Summary
36 patients with interstitial lung disease will be randomized to 1 weeks treatment with
morphine hydrochloride as oral linctus 5 mg, four times a day, and 5 mg as needed up to 4
times a day, or corresponding doses of placebo.
VAS score for dyspnea will be evaluated after 1 hour and 1 week at follow up. Other
questionnaires will also be evaluated (GAD-7, K-BUILD, Leicester score)